Eli Lilly and Company (NYSE: LLY) stock closed at 333.6 per share at the end of the most recent trading day (a 1.34% change compared to the prior day closing price) with a volume of 3.41M shares and market capitalization of 317.26B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 19500 people. Eli Lilly and Company CEO is David A. Ricks.

The one-year performance of Eli Lilly and Company stock is 15.18%, while year-to-date (YTD) performance is -8.81%. LLY stock has a five-year performance of 326.38%. Its 52-week range is between 276.83 and 384.44, which gives LLY stock a 52-week price range ratio of 52.32%

Eli Lilly and Company currently has a PE ratio of 54.60, a price-to-book (PB) ratio of 34.25, a price-to-sale (PS) ratio of 15.65, a price to cashflow ratio of 43.00, a PEG ratio of 2.32, a ROA of 13.67%, a ROC of 24.78% and a ROE of 72.51%. The company’s profit margin is 20.28%, its EBITDA margin is 29.00%, and its revenue ttm is $21.24 Billion , which makes it $22.35 revenue per share.

Of the last four earnings reports from Eli Lilly and Company, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.67 for the next earnings report. Eli Lilly and Company’s next earnings report date is 27th Apr 2023.

The consensus rating of Wall Street analysts for Eli Lilly and Company is Strong Buy (1.25), with a target price of $384, which is +15.31% compared to the current price. The earnings rating for Eli Lilly and Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eli Lilly and Company has a dividend yield of 1.29% with a dividend per share of $4.52 and a payout ratio of 47.00%.

Eli Lilly and Company has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.11, ATR14 : 7.95, CCI20 : 111.92, Chaikin Money Flow : -0.04, MACD : -1.82, Money Flow Index : 91.31, ROC : 5.89, RSI : 56.79, STOCH (14,3) : 94.77, STOCH RSI : 1.00, UO : 50.54, Williams %R : -5.23), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Alonzo Weems (Option Excercise at a value of $0), Alonzo Weems (Sold 2 968 shares of value $932 361 ), Anat Hakim (Option Excercise at a value of $0), Anne Nobles (Option Excercise at a value of $0), Anne Nobles (Sold 5 000 shares of value $1 723 075 ), Daniel M. Skovronsky (Option Excercise at a value of $0), David A. Ricks (Option Excercise at a value of $0), Diogo Rau (Option Excercise at a value of $0), Donald A. Zakrowski (Sold 4 600 shares of value $1 422 362 ), Edgardo Hernandez (Option Excercise at a value of $0), Eric Dozier (Option Excercise at a value of $0), Jackson P. Tai (Buy at a value of $199 549), Jacob S. Van Naarden (Option Excercise at a value of $0), Johna L. Norton (Option Excercise at a value of $0), Leigh Ann Pusey (Option Excercise at a value of $0), Michael B. Mason (Option Excercise at a value of $0), Patrik Jonsson (Option Excercise at a value of $0)